Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-20
2007-02-20
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252100, C514S255060
Reexamination Certificate
active
09807277
ABSTRACT:
The present invention relates generally to a method of retarding, reducing or otherwise inhibiting viral functional activity and, more particularly, to a method of reducing, retarding or otherwise inhibiting viral functional activity by down-regulating Vpu ion channel functional activity. Even more particularly, the present invention provides a method of treating HIV infection or AIDS by inhibiting Vpu ion channel mediated HIV replication.
REFERENCES:
patent: 4085211 (1978-04-01), Crago et al.
patent: 5215991 (1993-06-01), Burke
patent: 5506231 (1996-04-01), Lipton
patent: 07025768 (1995-01-01), None
patent: WO 90/09792 (1990-09-01), None
patent: WO 95/27510 (1995-10-01), None
patent: WO 95/27510 (1995-10-01), None
Balliet, J. W., et al., “Distinct Effects in Primary Macrophages and Lymphocytes of the Human Immunodeficiency virus Type 1 Accessory Gensevpr, vpu, andnef: Mutational analysis of a primary HIV-1 Isolate”,Virology, 200:623-631 (1994).
Barry, M., et al., “Antiretroviral therapy for patients with HIV Disease”,Br J. Clin. Pharmacol., 45:221-228 (1998).
Benos, D.J., et al., “Envelope glycoprotein gp 120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: Implications for AIDS dementia complex”Proc. Natl. Acad. Sci. USA, 91:494-498 (1994).
Bour, S., et al., The Human Immunodeficiency Virus Type 1 Vpu Protein Specifically Binds to the Cytoplasmc Domain of CD4: Implications for the Mechanism of Degradation,J. Virol, 69(3):1510-1520 (1995).
Bubien, J.K., et al. “HIV—gp 120 activates large—conductance apamin sensitive potassium channels in rat astrocytes”Am. J. Physiol., 286(6, part 1): C1440-C1449 (1995).
Cragoe, E.J., et al., “Pryazine Diuretics. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarbozmides”,J. Med. Chem., 10:66-75(1967).
Deeks, S.G., “Practical Issues Regarding the Use of Antiretroval Therapy for HIV Infection”,West J. Med., 168:133-139 (1998).
Duff, K.C., et al, “The Transmembrane Domain of Influenza A M2 Protein Forms Amantadine-Sensitive Proton Channels in Planar Lipid Bilayers”,Virology, 190:485-489 (1992).
Ewart, G.D., et al., The Vpu Protein of Human Immunodeficiency Virus Type 1 Form Cation-Selective Ion Channels:,J. Virol., 70(10):7108-7115 (1996).
Fear, W.R. et al., “Differential Tropism and Chemokine Receptor Expression of Human Immunodeficiency Virus Type 1 in Neonatal Monocytes, Monocyte-Derived Macrophages, and Placental Macrophages”,J. Virol., 72(2):1334-1344 (1998).
Friborg, J., et al., “Functional Analysis of the Phosphorylation Sites on the Human Immunodeficiency Virus Type 1 Vpu Protein”,J. Acquir. Immun Defic. Syndr. Hum. Retrovirol., 8:10-22 (1995).
Grice, et al., “Ion channels formed by HIV-1 Vpu: a modelling and simulation study”,FEBS Lett, 405(3):299-304 (1997).
Hay,A.J., et al., “The molecular basis of the specific anti-influenza action of action of amantandine”EMBO, 4(11):3021-3024 (1985).
Jabbar, M.A., The Human Immunodeficiency Virus Type 1 Vpu Protein: Roles in Virus Release and CD4 Downregulation, Cleveland Clinic Foundation, Dept. of Molecular Biology, pp. 107-118.
Kelly, M.D., et al., “Cutting Edge: Dichotomous Effects of B-Chemokines on HIV Replication in Monoctyes and Monocyte-Derived Macrophages”,J. Immunol., 160:3091-3095 (1998).
Kleyman, T.R., et al, “Amiloride and its Analogs as Tools in Study of Ion Transport”,J. Membrane Biol.105:1-21(1988).
Klimkait, T., et al., “The Human Immunodeficiency viru Type 1-Specific ProteinvpuIs Required for Efficient Virus Maturation and Release”J. of Virology64(2):621-629 (1990).
Love, C.A., et al., “Stable high-copy-number bacteriophage λ promoter vectors for overproduction of proteins inEscherichia coli”, Gene, 176:49-53 (1996).
Lu, Y.A., et al., “Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system”,Mol. Immun., 28(6):623-630 (1991).
Makutonina, A., et al., “Human Immunodeficiency virus infection of T-Lymphoblastoid Cells Reduces Intracellular pH”J. Virol., 70(10):7049-7055 (1996).
Maldarelli, F., et al., “Human Immunodeficiency Virus Type 1 Vpu Protein Is an Oligomeric Type I Intgral Membrane Protein”Jr. of Virology67(8):5056-5061(1993).
Miles, S.A., “Long-Term Therapeutic Stratgies in HIV”,J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 16(Suppl 1): S36-S41(1997).
Miles, S.A., “Introduction”,J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.16 Suppl 1: S1-2 (1997).
Miller, R.H., et al., “HIV accessory proteins as therapeutic targets”,Nat. Med., 3(4):389-394 (1997).
Mitsuya, H., “Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection”,Enzyme Inhibition, 6:1-8 (1992).
Moore, J.P., et al., “Simulation of the HIV-1 VPU transmembrane domain as a pentameric bundle”,FEBS Lett, 431(2):143-148 (1998).
Moore, J.P., “Coreceptors: Implications for HIV Pathogensis and Therapy”,Science, 276:51-52 (1997).
Moyke, G.J., et al., “Antiretroviral therapy of HIV Infection”,Drugs, 55(3):383-404 (1998).
Perezella, M.A., et al., “Trimethoprim-sulfamethoxazole hyperkalemia is an important complication regardless of dose”Clinical Nephrology, 46(3):187-192 (1996).
Piller, S.C., et al., “Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers”,Proc. Natl. Acad. Sci, 93:111-115 (1996).
Pinto,L.H., et al., “Influenza Virus M2Protein Has Ion Channel Activity”,Cell 69:517-528 (1992).
Rachlis, A.R., et al., “Guidelines for antiretroviral therapy for HIV infection”,Cmaj, 158:496-505 (1998).
Rosen, B.P., ATP-coupled Solute Transport Systems.Escherichia coli and Salmonella typimurium: Cellular and Molecular Biology 1: editor: Neidart, American Society for Microbiology 760-767 (1987).
Sansom, M.S.P., et al., “Influenza virus M2protein: a molecular modelling study of the ion channel”,Protein Engineering6(1):65-74 (1993).
Schlanger, L.E., et al., “K+-sparing diuretic actions of trimethoprim: Inhibition of Na+channels in distal nephron cells”,Kidney International, 45:1070-1076 (1994).
Schubert, U. et al., “The Two Biological Activities of Human Immunodeficiency Virus Type 1 Vpu Protein Involve Two Separable Structural Domains”,J. Virol., 70(2):809-819 (1996a).
Schubert, U., et al., “The Human Immunodeficiency Virus Type I Encoded Vpu Protein is Phosophorylated by Casein Kinase-2 (CK-2) at Positions Ser52 and Ser56 within a Predicted α-Helix-Turnα-α-Helix-Motif”,J. Mol. Biol., 236:16-25 (1994).
Schubert, U., et al., “Human-immunodeficiency-virus-type-1-encoded Vpu is phosphorylated by casein Kinase II”,Eur. J. Biochem., 204:875-882 (1992).
Schubert, U., et al., “Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells”,FEBS Letters398:12-18 (1996).
Strebel, K., et al., “A Novel Gene of HIV-1,vpu, and Its 16-Kilodalton Product”,Science241:121-1223 (1988).
Sugrue, R.J., “Structural Characteristics of M3 Protein of Influenza A Viruses: Evidence That It Forms a Tetrametric Channel”,Virology180:617-624 (1991).
Thomas, M., et al., “HIV Integrase: a target for AIDS therapeutics”,Trends Biotechnol., 15:167-172 (1997).
Tosteson, M.T., et al., “Reconstruction of the Influenza Virus M2Ion Channel in Lipid Bilayers”,J. Membrane Biol.142:117-126 (1994).
Trono, D., “HIV Accessory Proteins: Leading Roles for the Supporting Cast”,Cell, 82:189-192 (1995).
Varadhachary, A., et al., “A rapid method for reconstitution of bacterial membr
Cox Graeme
Ewart Gary
Gage Peter
Australian National University
Wang Shengjun
LandOfFree
Method of modulating ion channel functional activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modulating ion channel functional activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modulating ion channel functional activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886629